BR9814435A - Novos esteróides antiestrogênicos e composições farmacêuticas associadas - Google Patents

Novos esteróides antiestrogênicos e composições farmacêuticas associadas

Info

Publication number
BR9814435A
BR9814435A BR9814435-9A BR9814435A BR9814435A BR 9814435 A BR9814435 A BR 9814435A BR 9814435 A BR9814435 A BR 9814435A BR 9814435 A BR9814435 A BR 9814435A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
steroids
new
antiestrogenic
compounds
Prior art date
Application number
BR9814435-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Masato Tanabe
Richard H Peters
Wan-Ru Chao
Ling Jong
Original Assignee
Stanford Res Inst Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stanford Res Inst Int filed Critical Stanford Res Inst Int
Publication of BR9814435A publication Critical patent/BR9814435A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
BR9814435-9A 1997-12-24 1998-12-23 Novos esteróides antiestrogênicos e composições farmacêuticas associadas BR9814435A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/998,877 US6054446A (en) 1997-12-24 1997-12-24 Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
PCT/US1998/027406 WO1999033859A2 (en) 1997-12-24 1998-12-23 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use

Publications (1)

Publication Number Publication Date
BR9814435A true BR9814435A (pt) 2004-08-10

Family

ID=25545637

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814435-9A BR9814435A (pt) 1997-12-24 1998-12-23 Novos esteróides antiestrogênicos e composições farmacêuticas associadas

Country Status (14)

Country Link
US (3) US6054446A (cg-RX-API-DMAC7.html)
EP (4) EP1310509B1 (cg-RX-API-DMAC7.html)
JP (4) JP2001525855A (cg-RX-API-DMAC7.html)
KR (1) KR100464739B1 (cg-RX-API-DMAC7.html)
CN (2) CN1332974C (cg-RX-API-DMAC7.html)
AU (1) AU749597C (cg-RX-API-DMAC7.html)
BR (1) BR9814435A (cg-RX-API-DMAC7.html)
CA (1) CA2281844C (cg-RX-API-DMAC7.html)
DE (2) DE69839893D1 (cg-RX-API-DMAC7.html)
HU (1) HUP0100136A3 (cg-RX-API-DMAC7.html)
IL (1) IL136972A0 (cg-RX-API-DMAC7.html)
NO (1) NO317978B1 (cg-RX-API-DMAC7.html)
RU (1) RU2233288C2 (cg-RX-API-DMAC7.html)
WO (1) WO1999033859A2 (cg-RX-API-DMAC7.html)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
ATE506986T1 (de) * 1999-08-13 2011-05-15 Curadis Gmbh Substanzen und mittel zur positiven beeinflussung von kollagen
US7087592B1 (en) 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
AUPQ342599A0 (en) * 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
WO2001058919A2 (en) * 2000-02-11 2001-08-16 Sri International Synthesis of anti-estrogenic and other therapeutic steroids from 21-hydroxy-19-norpregna-4-en-3-one
AU2001248849A1 (en) 2000-04-24 2001-11-07 Kyowa Hakko Kogyo Co. Ltd. Estra-1,3,5(10)-triene derivatives
AU2001269953A1 (en) * 2000-06-20 2002-01-02 United States Postal Service Systems and methods for electronic message content identification
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
ATE361310T1 (de) * 2000-11-03 2007-05-15 Univ Washington Östronderivate mit zellschützender wirkung
AU2001288386B2 (en) * 2000-11-27 2006-11-02 Entremed, Inc. 2-substituted estrogens as antiangiogenic agents
JP2002241395A (ja) * 2001-02-16 2002-08-28 Taiho Yakuhin Kogyo Kk エストラ−４，６−ジエン−３，１７−ジオンの製造方法
WO2003039455A2 (en) * 2001-11-06 2003-05-15 Applied Research Systems Ars Holding N.V. Methods of treating endometreosis
US20050002900A1 (en) * 2001-11-06 2005-01-06 Grace Wong Method of treating estrogen responsive breast cancer
EP1470151B1 (en) * 2002-01-21 2009-12-30 N.V. Organon Process for the preparation of 7-alpha-methylsteroids
DE10307103A1 (de) * 2003-02-19 2004-09-09 Schering Ag Antitumor wirksame 2-substituierte D-Homostra-1,3,5(10)-trien-3-yl sulfamate
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
WO2005018575A2 (en) * 2003-08-26 2005-03-03 Board Of Regents, The University Of Texas System Estrogen receptor modulators and uses thereof
WO2005089256A2 (en) 2004-03-12 2005-09-29 Entremed, Inc. Antiangiogenic agents
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
EP2468318A1 (en) * 2005-07-12 2012-06-27 DMI Biosciences, Inc. Methods and products for treatment of diseases
TW200740442A (en) * 2005-08-29 2007-11-01 Taiho Pharmaceutical Co Ltd Therapeutic agent for hypertension
TW200804405A (en) * 2005-10-27 2008-01-16 Taiho Pharmaceutical Co Ltd Process for production of steroid compound
AU2007227256B2 (en) 2006-03-20 2012-10-04 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
EA017385B1 (ru) 2007-10-16 2012-12-28 Репрос Терапьютикс Инк. Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
KR101877041B1 (ko) 2009-06-22 2018-07-10 앰피오 파마슈티컬스 인코퍼레이티드 혈관 과투과성과 부종 및 이로부터 발생하는 다른 부작용을 저해하는 방법
RU2422455C1 (ru) * 2009-10-13 2011-06-27 Федеральное государственное образовательное учреждение высшего профессионального образования Санкт-Петербургский государственный университет ДИАЦЕТАТ РАЦЕМИЧЕСКОГО 3,17β-ДИГИДРОКСИ-7α,18-ДИМЕТИЛ-6-ОКСАЭСТРА-1,3,5( 10 ),8(9)-ТЕТРАЕНА, ОБЛАДАЮЩИЙ ОСТЕОПРОТЕКТОРНЫМ, ГИПОХОЛЕСТЕРИНЕМИЧЕСКИМ И АНТИОКСИДАНТНЫМ ДЕЙСТВИЕМ
AU2011242988B2 (en) * 2010-04-19 2013-02-07 Sri International Compositions and method for the treatment of multiple myeloma
EP2582371B1 (en) 2010-06-16 2019-10-16 Endorecherche, Inc. Methods of treating or preventing estrogen-related diseases
US20130123222A1 (en) * 2011-11-10 2013-05-16 Sri International, Inc. Synergistic Anti-Cancer Activity of SR16388 with Anti-Mitotic Drugs
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013225869B2 (en) 2012-02-29 2017-06-08 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AU2013361338A1 (en) 2012-12-19 2015-08-06 Ampio Pharmaceuticals, Inc. Method for treatment of diseases
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
KR20170005819A (ko) 2014-05-22 2017-01-16 쎄러퓨틱스엠디, 인코퍼레이티드 천연 복합 호르몬 대체 제형 및 요법
KR20180059427A (ko) 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen
WO2017096025A1 (en) 2015-12-02 2017-06-08 Helix Twelve Pharmaceuticals Corporation, Inc. Norpregnane derivatives for the risk reduction of breast cancer
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
CN107805247B (zh) * 2017-10-31 2020-09-29 上海长征富民金山制药有限公司 一种用于制备抗肾纤维化药物和/或抗慢性肾病药的β-咔啉化合物的制备工艺及其应用
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE84180C (cg-RX-API-DMAC7.html) *
FR943462A (fr) * 1946-03-08 1949-03-09 Ford Dispositif d'évacuation de l'eau pour glaces de voiture automobile
US2666769A (en) * 1952-09-27 1954-01-19 Searle & Co 17-glycolyl-estradiols
US2840581A (en) * 1956-12-17 1958-06-24 Upjohn Co Carbonyloxy steroids
NL294517A (cg-RX-API-DMAC7.html) * 1962-06-25 1900-01-01
FR3031M (fr) 1963-05-08 1964-12-28 Roussel Uclaf Nouveau médicament notamment pour le traitement de l'hypercholestérolémie et des troubles en résultant.
FR1453210A (fr) 1963-05-08 1966-06-03 Roussel Uclaf Nouveaux aminostéroïdes et procédé de préparation
FR3012M (fr) * 1963-05-13 1964-12-21 Roussel Uclaf Nouveaux médicaments doués notamment d'activité hypocholestérolémiante.
US3271426A (en) * 1963-06-28 1966-09-06 Schering Corp Novel androstane oximino ethers and methods for their manufacture
NL125069C (cg-RX-API-DMAC7.html) * 1963-12-24
FR1512326A (fr) * 1964-03-27 1968-02-09 Roussel Uclaf Nouveaux stéroïdes azotés et procédé de préparation
US3271392A (en) * 1965-09-14 1966-09-06 American Home Prod 17alpha-[3'-furyl]-estrogens
US3318917A (en) * 1965-11-12 1967-05-09 Searle & Co 17alpha-(4-alkoxy-3-buten-1-ynyl)estra-1, 3, 5(10)-triene-3, 17beta-diols and derivatives thereof
US3405147A (en) * 1966-02-25 1968-10-08 Searle & Co 17-phenylaliphatylestra-1, 3, 5(10)-trien-3-ols, 16-dehydro derivatives correspondingand esters thereof
US3398138A (en) * 1966-05-24 1968-08-20 American Home Prod Novel cardenolides and derivatives
US3448126A (en) * 1967-02-27 1969-06-03 Searle & Co 3-oxygenated 19-norpregna-1,3,5(10),17(20)-tetraen-21-als and enol esters thereof
US3536703A (en) * 1968-09-11 1970-10-27 Searle & Co N - (3 - alkoxy - 19 - norpregna - 1,3,5(10),17(20) - tetraen - 21 - yl)amines and derivatives thereof
GB1305752A (cg-RX-API-DMAC7.html) * 1970-03-06 1973-02-07
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
BE787343A (fr) * 1971-08-10 1973-02-09 Hoffmann La Roche Procede pour la preparation de 17-(2-halogenoethylidene)- steroides
US3927046A (en) * 1972-12-09 1975-12-16 Akzona Inc Novel 11,11-alkylidene steroids
US3859365A (en) * 1973-07-19 1975-01-07 Eastman Kodak Co Production of alkyl-substituted phenols from cyclohexenones
US3946052A (en) * 1975-06-16 1976-03-23 Stanford Research Institute 19-Norpregna- 1,3,5(10)-trien-3-ol and loweralkyl homologs thereof having postcoital antifertility activity
SU801517A1 (ru) * 1979-06-26 1988-12-30 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе Способ получени 14 @ -оксиандрост-4-ен-3,17-диона
US4705783A (en) * 1985-06-25 1987-11-10 Sri International 9α, 11β-substituted and 11β-substituted estranes
WO1987002367A2 (en) * 1985-10-18 1987-04-23 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
US5274089A (en) * 1985-10-18 1993-12-28 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
DE3741800A1 (de) * 1987-12-07 1989-06-15 Schering Ag 17-halogenmethylen-estratriene
US5371078A (en) * 1988-10-31 1994-12-06 Alcon Laboratories, Inc. Angiostatic steroids and methods and compositions for controlling ocular hypertension
US4882319A (en) * 1988-12-23 1989-11-21 Smithkline Beckman Corporation Phosphonic acid substituted aromatic steroids as inhibitors of steroid 5-α-reductase
DE3925507A1 (de) * 1989-07-28 1991-01-31 Schering Ag 14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
ATE162797T1 (de) * 1990-08-14 1998-02-15 Roussel Uclaf Neue 19-nor steroide, die eine amid tragende gruppe in der 11-beta-stelle haben, ihre herstellung, ihre verwendung als medikamente und pharmazeutische präparate davon
DE4132182A1 (de) * 1991-09-24 1993-03-25 Schering Ag 11(beta)-substituierte 14, 17-ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
FR2685332A1 (fr) * 1991-12-20 1993-06-25 Roussel Uclaf Nouveaux 19-nor sterouides ayant en position 11beta une chaine thiocarbonee, leur procede de preparation et les intermediaires et leur application a titre de medicaments.
RU2126794C1 (ru) 1992-03-11 1999-02-27 Нархекс Лимитед Аминопроизводные оксо- или гидроксизамещенных гидразинов, способ их получения и фармацевтические композиции для ингибирования ретровирусной протеазы
TW303299B (cg-RX-API-DMAC7.html) 1993-07-22 1997-04-21 Lilly Co Eli
US5554603A (en) * 1993-09-17 1996-09-10 The United States Of America As Represented By The Department Of Health And Human Services Orally active derivatives of 1,3,5(10)-estratriene
JPH07101977A (ja) * 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
US5447941A (en) 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
US5446053A (en) 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5461064A (en) 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5578613A (en) 1993-12-21 1996-11-26 Eli Lilly And Company Methods for inhibiting weight gain or inducing weight loss
US5593987A (en) 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5451589A (en) 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5591753A (en) 1994-01-28 1997-01-07 Eli Lilly And Company Combination treatment for osteoporosis
US5478847A (en) 1994-03-02 1995-12-26 Eli Lilly And Company Methods of use for inhibiting bone loss and lowering serum cholesterol
FR2718138B1 (fr) * 1994-04-01 1996-04-26 Roussel Uclaf Nouveaux stéroïdes comportant en position 20 une chaîne aminosubstituée, procédé et intermédiaires de préparation, application comme médicaments et compositions pharmaceutiques les renfermant.
US5612317A (en) * 1994-08-04 1997-03-18 Holick; Michael F. Method for delivering estrogen
GB9518858D0 (en) * 1995-09-14 1995-11-15 Pharmacia Spa Phenylsubstituted 4-azasteroid fluoroderivatives
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5945412A (en) * 1996-12-09 1999-08-31 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss
RU58668U1 (ru) 2006-06-05 2006-11-27 Открытое акционерное общество "Нижегородский машиностроительный завод" Водогрейный котел

Also Published As

Publication number Publication date
EP1847548A3 (en) 2012-09-12
WO1999033859A9 (en) 1999-09-23
NO317978B1 (no) 2005-01-17
JP2007269797A (ja) 2007-10-18
JP4718512B2 (ja) 2011-07-06
DE69839893D1 (de) 2008-09-25
WO1999033859A2 (en) 1999-07-08
HUP0100136A2 (hu) 2001-08-28
AU749597C (en) 2003-02-20
EP1310509A2 (en) 2003-05-14
JP2007051148A (ja) 2007-03-01
EP1056768B1 (en) 2003-03-19
AU749597B2 (en) 2002-06-27
NO20003254D0 (no) 2000-06-22
CN101130567A (zh) 2008-02-27
KR100464739B1 (ko) 2005-01-05
NO20003254L (no) 2000-08-21
JP3968114B2 (ja) 2007-08-29
JP4959276B2 (ja) 2012-06-20
US20020032181A1 (en) 2002-03-14
EP2305694A3 (en) 2013-04-17
EP1056768A2 (en) 2000-12-06
HUP0100136A3 (en) 2002-04-29
KR20000075580A (ko) 2000-12-15
JP2007031446A (ja) 2007-02-08
CN1332974C (zh) 2007-08-22
IL136972A0 (en) 2001-06-14
CA2281844C (en) 2007-06-19
US6281205B1 (en) 2001-08-28
DE69812433T2 (de) 2004-02-12
CN1291196A (zh) 2001-04-11
AU2010499A (en) 1999-07-19
CA2281844A1 (en) 1999-07-08
CN101130567B (zh) 2011-11-23
EP1310509A3 (en) 2004-12-08
US6054446A (en) 2000-04-25
RU2233288C2 (ru) 2004-07-27
US6455517B1 (en) 2002-09-24
EP1310509B1 (en) 2008-08-13
WO1999033859A3 (en) 1999-12-23
DE69812433D1 (de) 2003-04-24
EP2305694A2 (en) 2011-04-06
EP1847548A2 (en) 2007-10-24
JP2001525855A (ja) 2001-12-11

Similar Documents

Publication Publication Date Title
BR9814435A (pt) Novos esteróides antiestrogênicos e composições farmacêuticas associadas
BR9813028A (pt) Agonistas de prostaglandina e seu uso para tratar distúrbios nos ossos
BR0009651A (pt) Composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, e, método para tratar artrite reumatóide e uma doença obstrutiva das vias aéreas
WO1996019458A3 (en) Steroid receptor modulator compounds and methods
BR0114410A (pt) Associação de um antagonista de receptor cb1 e de sibutramina, as composições farmacêuticas que os contêm e a respectiva utilização para o tratamento da obesidade
BR9807577A (pt) Método para prevenir e retardar o inìcio da doença de alzheimer e sua composição
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
BR0009814A (pt) Processo para tratar de uma doença associada com o receptor-beta estrogênico
BR0307429A (pt) Composto, uso do mesmo, composição farmacêutica, e, método para o tratamento de distúrbios ou doenças relacionadas com receptor de histamina h3
YU7797A (sh) Kombinovana terapija za osteoporozu
FI970526L (fi) Estra-1,3,5(10)-trieenijohdannaiset, niiden valmistusmenetelmät sekä näitä yhdisteitä sisältävät farmaseuttiset koostumukset
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
BR9406566A (pt) Composição farmacêutica uso de progesterona e/ou 17 - - estradiol e processo para a fabricação de uma preparação farmacêutica
EE200000050A (et) Ravimkoostised, kasutusvalmis komplektid ja meetodid peaaju neurovaskulaarsete häirete ja lihaspingepeavalu inhibeerimiseks
BR9913457A (pt) Neuroproteção
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
BR9909486A (pt) Compostos calcilìticos
BR0011928A (pt) Composto, composição farmacêutica, uso de, um composto e métodos para o tratamento de complicações diabéticas, para o tratamento ou a prevenção do desenvolvimento de condições de doença associadas com velocidade de condução neuronial prejudicada e de neuropatia diabética
BR9809234A (pt) Composto, composição farmacêutica, uso de um composto, processos para tratar ou prevenir doenças do sistema endocrinológico, para fabricar um medicamento, para preparar um composto e um conjunto, conjunto, e, uso do mesmo.
BR0012478A (pt) Derivados de aminotiazóis, sua preparação e composição farmacêuticas contendo os mesmos
BR9812780A (pt) 2-aril-3-aroilbenzo[b]tiofenos úteis para o tratamento de sìndrome da perda de estrogênio
BR0316070A (pt) Composto, composição farmacêutica, uso de um composto e, método para modular mchr
BR9812404A (pt) Combinação de um antagonista de endotelina, preparação farmacêutica, processo para preparar uma preparação farmacêutica, e , uso de uma combinação de um bloqueador de beta receptor e de um antagonista de endotelina
BR9911103A (pt) Antiestrógenos, processo para sua preparação e seu uso farmacêutico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT. CL. C07J 41/00, C07J 43/00.

Ipc: A61K 31/56 (2006.01), A61K 31/57 (2006.01), A61K 3

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements